Neuland Laboratories has announced a significant leadership change with Saharsh Davuluri taking over as the Chief Executive Officer and Managing Director. This transition marks a new chapter for the company as it embarks on the next phase of its contract development and manufacturing organisation (CDMO) growth.
Saharsh Davuluri, who has been with Neuland Laboratories for over 18 years, will lead the company as it positions itself as a premier global API process development and commercial manufacturing specialist. Under his leadership, Neuland has transformed into a new chemical entity (NCE)-focused drug substance CDMO, securing numerous commercial manufacturing contracts with global innovators. This change reflects the increasing demand for Neuland’s expertise in process chemistry, scale-up, and reliable commercial supply.
Saharsh succeeds Sucheth Davuluri, who has been instrumental in transforming Neuland into a CDMO-focused business model. Sucheth will now assume the role of Executive Vice Chairman of the company.
In his new role, Saharsh aims to accelerate Neuland’s growth transformation over the next five years. The company has already committed to a four-phase expansion of commercial peptide capacity and is doubling its process development capabilities. “The secret sauce behind our recent commercial success has been our strong reputation for specialist process chemistries, accelerated development timelines, and consistent commercial supply,” Saharsh commented.
Neuland is set to embark on an aggressive expansion phase and could secure several more commercial NCE contracts, including peptides, over the next one to two years, pending customer approvals. The company operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D facility, with 1218 KL of installed capacity and more than 20 commercial contracts across APIs and intermediates.
Saharsh emphasised the importance of aligning Neuland’s CDMO investment approach with the innovation pipelines of its customers, stating, “Our ambition is to become one of the world’s top five API-focused CDMOs over the next decade.”
Neuland Laboratories, listed on the NSE and BSE in India, is a specialist API CDMO partner for big pharma and biotech, delivering world-class process development and commercial supply services for complex molecules and New Chemical Entities.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).